Autonomix Medical Gets Patent for Signal Devices

The Woodlands, Texas-based medical device company received U.S. Patent No. 12,793,841 for circuitry that captures and processes physiological signals.

Updated on Nov. 10, 2026 in Healthcare

Close shot of a bare green circuit board with copper traces on a white laboratory bench, lit by soft window daylight.
Autonomix Medical, a Woodlands, Texas company, received U.S. Patent No. 12,793,841 for circuitry that captures and processes physiological signals. AI Illustration. Upload story photo >

Autonomix Medical, a medical device company based in The Woodlands, Texas, was granted U.S. Patent No. 12,793,841, titled "Medical Devices With Circuitry For Capturing And Processing Physiological Signals." The patent covers devices and methods for capturing and processing physiological signals through sensing and processing circuitry and builds on the company's existing intellectual property portfolio.

Why it matters

The patent strengthens Autonomix's intellectual property position for its investigational technology, which has not yet been cleared for marketing in the United States. The company says the technology could give physicians greater insight into neural activity.

Patent No. 12,793,841 was announced November 10, 2026, and was issued to Autonomix Medical, which trades on NASDAQ under the ticker AMIX. The source does not disclose the company's financial metrics or the patent's expected commercial value.

The players

Autonomix Medical, Inc. (NASDAQ: AMIX)

A medical device company headquartered in The Woodlands, Texas, focused on investigational technologies for capturing and processing physiological signals.

The details

The patented architecture uses distributed processing modules, configurable sensing capabilities and efficient data transmission to acquire and process signals near their biological source. The company says the technology may apply to cardiovascular interventions, electrophysiology and pain management, and it continues to explore additional clinical uses.

Timeline

  1. May 27, 2026: Autonomix filed its most recent Form 10-K annual report with the SEC.

  2. November 10, 2026: Autonomix announced issuance of U.S. Patent No. 12,793,841.

Industry Position

The patent extends Autonomix's existing U.S. and international intellectual property portfolio, adding protection for circuitry that captures and processes physiological signals. Its investigational status means the company's broader healthcare market position will depend on regulatory clearance it has not yet received.

Patients and clinicians are not yet able to access this technology, since it remains investigational and has not been cleared for U.S. marketing. The patent signals a longer development path before any clinical use could reach patients in Texas or elsewhere.

The takeaway

A patent confirms protected intellectual property but does not by itself signal regulatory approval. Readers should watch for any future clearance announcements before assuming clinical availability.

Further reading

Explore more Texas healthcare industry news on the company's regional market and recent developments.